Welcome to our dedicated page for 60 Degrees Pharm news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharm stock.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
Recent achievements include their Chief Executive Officer, Geoff Dow, PhD, planning a clinical trial to study the use of tafenoquine in treating human babesiosis, a tick-borne disease. The Company has been focused on developing new medicines for rare infectious diseases and collaborating with renowned research organizations in the U.S., Australia, and Singapore.
Financially, 60 Degrees Pharmaceuticals recently reported results for the first fiscal quarter of 2024, showcasing a strong commitment to advancing treatments for infectious diseases.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced a 1-for-5 reverse stock split of its common stock, effective February 24, 2025. The primary purpose is to comply with Nasdaq's $1.00 minimum bid price requirement to maintain listing. The stock will continue trading under 'SXTP' with a new CUSIP number 83006G401.
The reverse split will automatically convert every five current shares into one new share. Proportional adjustments will be made to outstanding equity awards, warrants, convertible notes, and shares under stock incentive plans. The split won't alter the par value, authorized share count, or stockholders' percentage ownership. No fractional shares will be issued; all will be rounded up to the next whole share.
Stockholders don't need to take action, as positions will be automatically adjusted. The company notes there's no guarantee it will meet the minimum bid requirement.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced FDA's non-objection to import KODATEF® (tafenoquine) from Australia as a one-time measure to prevent potential supply disruptions of ARAKODA® in the U.S. market. Both medications are identical antimalarial drugs for adults 18 and older, with ARAKODA being the U.S. brand name and KODATEF being the Australian version.
The company plans to import a five-month supply of KODATEF while increasing ARAKODA manufacturing capacity, responding to growing product demand and awareness in the U.S. This proactive measure aims to ensure continuous availability of tafenoquine for malaria prophylaxis to healthcare providers.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has closed a registered direct offering priced at-the-market, raising approximately $1.075 million in gross proceeds through the sale of 1,503,500 common stock shares at $0.715 per share. The company also issued unregistered short-term warrants in a concurrent private placement to purchase up to 1,503,500 shares at $0.59 per share, exercisable for 24 months.
This offering, combined with previous fundraising since early 2025, brings total gross proceeds to $2.118 million. The company plans to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for the offering.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced a registered direct offering of 1,503,500 shares of common stock at $0.715 per share, priced at-the-market under Nasdaq rules. The company will also issue unregistered short-term warrants in a concurrent private placement to purchase up to 1,503,500 shares at $0.59 per share, exercisable for 24 months upon issuance.
The offering, expected to close around February 6, 2025, will generate gross proceeds of $1.075 million before deducting placement agent fees and expenses. H.C. Wainwright & Co. is serving as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has closed its previously announced registered direct offering, raising approximately $1.043 million in gross proceeds. The offering included 1,021,549 shares of common stock at $1.021 per share, priced at-the-market under Nasdaq rules.
In a concurrent private placement, the company issued unregistered short-term warrants to purchase up to 2,043,098 shares of common stock at an exercise price of $0.771 per share. These warrants are exercisable upon issuance and will expire after 24 months.
H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The offering was conducted under a shelf registration statement that became effective on July 18, 2024.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced a registered direct offering priced at-the-market under Nasdaq rules, consisting of 1,021,549 shares of common stock at $1.021 per share. The company will also issue unregistered short-term warrants in a concurrent private placement to purchase up to 2,043,098 shares at $0.771 per share, exercisable for 24 months upon issuance.
The offering, expected to close around January 30, 2025, will generate gross proceeds of $1.043 million before deducting fees and expenses. H.C. Wainwright & Co. is serving as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has received IRB approval for a Phase II clinical study to evaluate ARAKODA® (tafenoquine) in treating chronic babesiosis. The open-label study (NCT06656351) will assess the drug's efficacy and safety over 90 days in outpatient settings, targeting patients with presumptive chronic babesiosis who have experienced significant functional impairment for at least six months.
Patient enrollment is scheduled to begin in Q3 2025. The company estimates the total cumulative addressable market through December 2035 (U.S. patent protection end) exceeds 400,000 patients. The study aims to address an unmet medical need, as there are currently no approved treatment options for chronic babesiosis, a condition that is emerging in new regions of the U.S.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has initiated enrollment in an expanded access clinical study for tafenoquine in treating persistent babesiosis. The study aims to confirm the drug's effectiveness in patients who have failed standard care treatment and are at high relapse risk.
Recent clinical case studies showed tafenoquine achieved an 80% cure rate in five high-risk patients with persistent, relapsing babesiosis who failed prior treatments. Babesiosis, a potentially life-threatening tick-borne disease transmitted by the black-legged tick, shows increasing incidence in the Northeast U.S.
The company estimates the total cumulative accessible market through December 2035 (U.S. patent protection end) may exceed 400,000 patients. While tafenoquine is currently approved as ARAKODA for malaria prophylaxis, it has not been proven effective or received FDA approval for babesiosis treatment or prevention.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) and Tufts Medical Center have signed a Patent License Agreement to develop and commercialize tafenoquine for babesiosis treatment and prevention. The agreement establishes joint patent ownership, with 60 Degrees leading global commercialization efforts and holding exclusive rights. Tufts MC will receive royalties on net sales while retaining research rights. The collaboration aims to address an unmet medical need, as tafenoquine could potentially become the first prophylaxis available for babesiosis, a tick-borne disease affecting red blood cells. The agreement follows initial research collaboration between both organizations, resulting in U.S. Provisional Patent Application No. 63/461,060.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has expanded its tafenoquine clinical trial for babesiosis to Brigham and Women's Hospital in Boston. The double-blind, placebo-controlled study will evaluate tafenoquine combined with standard treatment for hospitalized babesiosis patients. The trial is also ongoing at Tufts Medical Center, Yale University, and Rhode Island Hospital.
The study aims to recruit 24-33 patients in summer 2025, with an interim analysis expected in early 2026. The main endpoints are time to sustained clinical resolution of symptoms and molecular cure. Recent case studies suggest tafenoquine with standard care shows high cure rates in immunosuppressed patients with relapsing babesiosis. The company estimates the total accessible market through December 2035 could exceed 400,000 patients.
FAQ
What is the current stock price of 60 Degrees Pharm (SXTPW)?
What is 60 Degrees Pharmaceuticals focused on?
What recent achievement did 60 Degrees Pharmaceuticals announce?
Who is leading the efforts at 60 Degrees Pharmaceuticals?
